Kletkiewicz, H
LBA 10 Luong, T
Effect of CIN-109, a novel GDF-15 analog, on body weight and composition in subjects with obesity
Patented in 1998 (expired 2018), BPC-157 is also referred to as PL 14736, PL-10, or Bepecin in the scientific literature [3, 4, 5]
SGLT2 inhibitors are drugs that reduce glucose reabsorption in the kidney by blocking the protein SGLT2, the main sodium-glucose cotransporter expressed in the kidney tubules
Conflict of interest The author has provided advisory services to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk, and has received lecture honoraria from Bristol Myers Squibb, Novartis and the above-mentioned companies